{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:31:50Z","timestamp":1780378310940,"version":"3.54.1"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fujian Provincial Clinical Research Center for Cancer Radiotherapy and Immunotherapy","award":["2020Y2012"],"award-info":[{"award-number":["2020Y2012"]}]},{"name":"National Clinical Key Specialty Construction Program"},{"name":"Fujian Clinical Research Center for Radiation and Therapy of Digestive, Respiratory and Genitourinary Malignancies","award":["2021Y2014"],"award-info":[{"award-number":["2021Y2014"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473376"],"award-info":[{"award-number":["82473376"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["12374405"],"award-info":[{"award-number":["12374405"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Major Scientific Research Program for Young and Middle-aged Health Professionals of Fujian Province","award":["2021ZQNZD010"],"award-info":[{"award-number":["2021ZQNZD010"]}]},{"name":"Joint Funds for the Innovation of Science and Technology","award":["2021Y9196"],"award-info":[{"award-number":["2021Y9196"]}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2023J011267"],"award-info":[{"award-number":["2023J011267"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2024J011108"],"award-info":[{"award-number":["2024J011108"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2024J011086"],"award-info":[{"award-number":["2024J011086"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"name":"High-level Talent Training Program of Fujian Cancer Hospital","award":["2022YNG07"],"award-info":[{"award-number":["2022YNG07"]}]},{"name":"Middle-aged Experts with Outstanding Contributions in Fujian Province\u2019s Health","award":["F23R-TG01-01"],"award-info":[{"award-number":["F23R-TG01-01"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Treatment-related thyroid dysfunction (trTD) frequently occurs in advanced nasopharyngeal carcinoma (NPC) patients treated with PD-1 inhibitors. Its clinical features, incidence, and prognostic value remain unclear. This study aimed to characterize trTD and assess its impact on survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 168 advanced NPC patients who received PD-1 inhibitor therapy between 2019 and 2022. Cox proportional hazards models and Kaplan\u2013Meier analysis were used to assess the prognostic significance of trTD. Clinical factors associated with trTD were identified through logistic regression. A predictive nomogram was constructed and evaluated using receiver operating characteristic (ROC) and calibration curves. Spearman correlation analysis was performed to assess the dynamic relationship between thyroid function indicators and treatment duration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>TrTD developed in 49.4% of patients, mostly mild, including hyperthyroidism, hypothyroidism, and biphasic dysfunction. TrTD was independently associated with improved progression free survival (PFS). Female, elevated ALB, ALT, and TBIL were independent risk factors for trTD. The nomogram constructed by combining these factors and thyroid indicators had good prediction accuracy (AUC\u2009=\u20090.781). Dynamic analysis revealed that TSH levels significantly increased after the fourth treatment cycle, preceding changes in FT3 and FT4, suggesting TSH as a potential early biomarker for trTD onset.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study identifies trTD as a common event associated with improved survival in advanced NPC patients treated with PD-1 inhibitors. A predictive nomogram and early TSH elevation provide valuable tools for risk stratification and personalized immunotherapy monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag066","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T12:44:15Z","timestamp":1771937055000},"source":"Crossref","is-referenced-by-count":1,"title":["Predictive modeling of treatment-related thyroid dysfunction and prognostic implication in advanced nasopharyngeal carcinoma with PD-1 inhibitors"],"prefix":"10.1093","volume":"31","author":[{"given":"Yubin","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center) , Fujian 350014, People's Republic of","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center) , Fujian 350014, People's Republic of","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center) , Fujian 350014, People's Republic of","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Xiang\u2019an Hospital of Xiamen University, School of Medicine, Xiamen University , Xiamen 361005, People's Republic of","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Abidullah","family":"Warsi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center) , Fujian 350014, People's Republic of","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronghui","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center) , Fujian 350014, People's Republic of","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoying","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center) , Fujian 350014, People's Republic of","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peidong","family":"Ou","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center) , Fujian 350014, People's Republic of","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuibo","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center) , Fujian 350014, People's Republic of","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7660-6955","authenticated-orcid":false,"given":"Sufang","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital (Fujian Branch of Fudan University Shanghai Cancer Center) , Fujian 350014, People's Republic of","place":["China"]},{"name":"Fujian Key Laboratory of Translational Cancer Medicine , Fujian 350014, People's Republic of","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"2026032713575075100_oyag066-B1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"key":"2026032713575075100_oyag066-B2","doi-asserted-by":"crossref","first-page":"6427","DOI":"10.7150\/thno.53229","article-title":"Neoantigen landscape in metastatic nasopharyngeal carcinoma","volume":"11","author":"Lin","year":"2021","journal-title":"Theranostics"},{"key":"2026032713575075100_oyag066-B3","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/imr.13247","article-title":"Immune-related adverse events after immune check point inhibitors: understanding the intersection with autoimmunity","volume":"318","author":"Singh","year":"2023","journal-title":"Immunol Rev"},{"key":"2026032713575075100_oyag066-B4","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1001\/jama.2023.20181","article-title":"Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: the JUPITER-02 randomized clinical trial","volume":"330","author":"Mai","year":"2023","journal-title":"JAMA"},{"key":"2026032713575075100_oyag066-B5","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1200\/JCO.20.02712","article-title":"Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02)","volume":"39","author":"Wang","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026032713575075100_oyag066-B6","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","article-title":"Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial","volume":"22","author":"Yang","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026032713575075100_oyag066-B7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.6004\/jnccn.2025.0007","article-title":"NCCN guidelines\u00ae insights: head and neck cancers, version 2.2025","volume":"23","author":"Colevas","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"2026032713575075100_oyag066-B8","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1016\/S0140-6736(24)00594-4","article-title":"Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial","volume":"403","author":"Liu","year":"2024","journal-title":"Lancet"},{"key":"2026032713575075100_oyag066-B9","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"2026032713575075100_oyag066-B10","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026032713575075100_oyag066-B11","doi-asserted-by":"crossref","first-page":"1381061","DOI":"10.3389\/fimmu.2024.1381061","article-title":"Clinical biomarkers for thyroid immune-related adverse events in patients with stage III and IV gastrointestinal tumors","volume":"15","author":"Xing","year":"2024","journal-title":"Front Immunol"},{"key":"2026032713575075100_oyag066-B12","doi-asserted-by":"crossref","first-page":"988","DOI":"10.4158\/EP12280.GL","article-title":"Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American association of clinical endocrinologists and the American thyroid association","volume":"18","author":"Garber","year":"2012","journal-title":"Endocr Pract"},{"key":"2026032713575075100_oyag066-B13","doi-asserted-by":"crossref","first-page":"107296","DOI":"10.1016\/j.intimp.2020.107296","article-title":"Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer","volume":"91","author":"Zhou","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"2026032713575075100_oyag066-B14","doi-asserted-by":"crossref","first-page":"e1742","DOI":"10.1002\/onco.13868","article-title":"Immune-related adverse events as clinical biomarkers in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors","volume":"26","author":"Martini","year":"2021","journal-title":"Oncologist"},{"key":"2026032713575075100_oyag066-B15","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026032713575075100_oyag066-B16","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1089\/thy.2019.0726","article-title":"Overt thyroid dysfunction and anti-thyroid antibodies predict response to anti-PD-1 immunotherapy in cancer patients","volume":"30","author":"Basak","year":"2020","journal-title":"Thyroid"},{"key":"2026032713575075100_oyag066-B17","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1200\/JCO.2017.73.3675","article-title":"Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study","volume":"35","author":"Hsu","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026032713575075100_oyag066-B18","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2017.77.0388","article-title":"Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the Mayo clinic phase 2 consortium (NCI-9742)","volume":"36","author":"Ma","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026032713575075100_oyag066-B19","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S1470-2045(18)30495-9","article-title":"Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials","volume":"19","author":"Fang","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026032713575075100_oyag066-B20","doi-asserted-by":"crossref","first-page":"110713","DOI":"10.1016\/j.radonc.2025.110713","article-title":"Reducing radiation-induced hypothyroidism by modified delineation of cervical lymphatic drainage area for nasopharyngeal carcinoma treated by intensity-modulated radiation therapy: 3 years\u2019 experience","volume":"204","author":"Lu","year":"2025","journal-title":"Radiother Oncol"},{"key":"2026032713575075100_oyag066-B21","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1007\/s00702-020-02260-5","article-title":"Hypothyroidism after radiation exposure: brief narrative review","volume":"127","author":"Reiners","year":"2020","journal-title":"J Neural Transm (Vienna)"},{"key":"2026032713575075100_oyag066-B22","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12916-022-02697-3","article-title":"Thyroid dysfunction in chinese nasopharyngeal carcinoma after anti-PD-1 therapy and its association with treatment response","volume":"21","author":"Chen","year":"2023","journal-title":"BMC Med"},{"key":"2026032713575075100_oyag066-B23","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1093\/jnci\/94.21.1614","article-title":"Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma","volume":"94","author":"Chan","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"2026032713575075100_oyag066-B24","first-page":"1188","article-title":"Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma","volume":"59","author":"Lo","year":"1999","journal-title":"Cancer Res"},{"key":"2026032713575075100_oyag066-B25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ijrobp.2022.04.052","article-title":"Radiation-induced hypothyroidism in patients with breast cancer after hypofractionated radiation therapy: a prospective cohort study","volume":"115","author":"Zhao","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026032713575075100_oyag066-B26","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-022-00357-7","article-title":"Hypothyroidism","volume":"8","author":"Chaker","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"2026032713575075100_oyag066-B27","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"2026032713575075100_oyag066-B28","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ccell.2023.04.014","article-title":"Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: a multicenter phase 3 trial (RATIONALE-309)","volume":"41","author":"Yang","year":"2023","journal-title":"Cancer Cell"},{"key":"2026032713575075100_oyag066-B29","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study, lancet","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"2026032713575075100_oyag066-B30","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"2026032713575075100_oyag066-B31","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial","volume":"16","author":"Rizvi","year":"2015","journal-title":"Lancet Oncol"},{"key":"2026032713575075100_oyag066-B32","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1200\/JCO.2015.63.7421","article-title":"Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study","volume":"34","author":"McDermott","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026032713575075100_oyag066-B33","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"2026032713575075100_oyag066-B34","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-21-3849","article-title":"Phase II multi-institutional clinical trial result of concurrent cetuximab and nivolumab in recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"28","author":"Chung","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026032713575075100_oyag066-B35","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ctrv.2003.12.003","article-title":"Radiotherapy-induced thyroid disorders","volume":"30","author":"Jereczek-Fossa","year":"2004","journal-title":"Cancer Treat Rev"},{"key":"2026032713575075100_oyag066-B36","doi-asserted-by":"crossref","first-page":"34170","DOI":"10.1007\/s11356-024-33504-6","article-title":"Changes in the structural and functional state of the thyroid gland of small mammals when exposed to low-intensity chronic radiation","volume":"31","author":"\u0415rmakova","year":"2024","journal-title":"Environ Sci Pollut Res Int"},{"key":"2026032713575075100_oyag066-B37","doi-asserted-by":"crossref","first-page":"ii98","DOI":"10.1093\/jrr\/rrx054","article-title":"Radiation-related thyroid autoimmunity and dysfunction","volume":"59","author":"Nagayama","year":"2018","journal-title":"J Radiat Res"},{"key":"2026032713575075100_oyag066-B38","first-page":"9","article-title":"Radiation-induced inflammation and autoimmune diseases","volume":"5","author":"Yahyapour","year":"2018","journal-title":"Mil Med Res"},{"key":"2026032713575075100_oyag066-B39","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026032713575075100_oyag066-B40","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/hed.23285","article-title":"Longitudinal study on the correlations of thyroid antibody and thyroid hormone levels after radiotherapy in patients with nasopharyngeal carcinoma with radiation-induced hypothyroidism","volume":"36","author":"Lin","year":"2014","journal-title":"Head Neck"},{"key":"2026032713575075100_oyag066-B41","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.oraloncology.2017.03.005","article-title":"Radiation-induced hypothyroidism after IMRT for nasopharyngeal carcinoma: clinical and dosimetric predictors in a prospective cohort study","volume":"68","author":"Zhai","year":"2017","journal-title":"Oral Oncol"},{"key":"2026032713575075100_oyag066-B42","first-page":"7","article-title":"Reinvigorating exhausted T cells by blockade of the PD-1 pathway","volume":"6","author":"Lee","year":"2015","journal-title":"For Immunopathol Dis Therap"},{"key":"2026032713575075100_oyag066-B43","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11684-016-0436-0","article-title":"Comprehensive profiling of EBV gene expression in nasopharyngeal carcinoma through paired-end transcriptome sequencing","volume":"10","author":"Hu","year":"2016","journal-title":"Front Med"},{"key":"2026032713575075100_oyag066-B44","doi-asserted-by":"crossref","first-page":"253","DOI":"10.21037\/jtd-23-1092","article-title":"Immune-related thyroid dysfunction in patients with non-small cell lung cancer","volume":"16","author":"Cai","year":"2024","journal-title":"J Thorac Dis"},{"key":"2026032713575075100_oyag066-B45","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/CAD.0000000000001716","article-title":"Correlative analysis of immune-related thyroid dysfunction and prognosis in patients with advanced esophageal squamous cell carcinoma","volume":"36","author":"Da","year":"2025","journal-title":"Anticancer Drugs"},{"key":"2026032713575075100_oyag066-B46","doi-asserted-by":"crossref","first-page":"e240064","DOI":"10.1530\/ERC-24-0064","article-title":"Thyroid dysfunction caused by immune checkpoint inhibitors improves cancer outcomes","volume":"31","author":"Garc\u00eda-Go\u00f1i","year":"2024","journal-title":"Endocr Relat Cancer"},{"key":"2026032713575075100_oyag066-B47","doi-asserted-by":"crossref","first-page":"1495460","DOI":"10.3389\/fimmu.2024.1495460","article-title":"Immune-related thyroid dysfunction as a positive prognostic factor for patients with lung cancer in China: a real-world retrospective study","volume":"15","author":"Guo","year":"2024","journal-title":"Front Immunol"},{"key":"2026032713575075100_oyag066-B48","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41586-023-06816-9","article-title":"Dictionary of immune responses to cytokines at single-cell resolution","volume":"625","author":"Cui","year":"2024","journal-title":"Nature"},{"key":"2026032713575075100_oyag066-B49","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1158\/2326-6066.CIR-20-0969","article-title":"Regulatory T-cell transcriptomic reprogramming characterizes adverse events by checkpoint inhibitors in solid tumors","volume":"9","author":"Grigoriou","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"2026032713575075100_oyag066-B50","doi-asserted-by":"crossref","first-page":"e3704","DOI":"10.1210\/clinem\/dgab263","article-title":"Thyroid immune-related adverse events following immune checkpoint inhibitor treatment","volume":"106","author":"Muir","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2026032713575075100_oyag066-B51","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM199607113350206","article-title":"Chronic autoimmune thyroiditis","volume":"335","author":"Dayan","year":"1996","journal-title":"N Engl J Med"},{"key":"2026032713575075100_oyag066-B52","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.lungcan.2019.03.020","article-title":"Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab","volume":"132","author":"Oyanagi","year":"2019","journal-title":"Lung Cancer"},{"key":"2026032713575075100_oyag066-B53","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.2217\/fon-2020-0861","article-title":"Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data","volume":"17","author":"Shimozaki","year":"2021","journal-title":"Future Oncol"},{"key":"2026032713575075100_oyag066-B54","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.3390\/cancers13061308","article-title":"Neutrophil-to-lymphocyte ratio predicts development of immune-related adverse events and outcomes from immune checkpoint blockade: a case-control study","volume":"13","author":"Lee","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026032713575075100_oyag066-B55","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.tmrv.2009.09.005","article-title":"Albumin usage in clinical medicine: tradition or therapeutic?","volume":"24","author":"Farrugia","year":"2010","journal-title":"Transfus Med Rev"},{"key":"2026032713575075100_oyag066-B56","first-page":"2786","article-title":"Familial dysalbuminemic hyperthyroxinemia in a swiss family caused by a mutant albumin (R218P) shows an apparent discrepancy between serum concentration and affinity for thyroxine","volume":"85","author":"Pannain","year":"2000","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag066\/67112119\/oyag066.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/4\/oyag066\/67112119\/oyag066.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/4\/oyag066\/67112119\/oyag066.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T17:58:04Z","timestamp":1774634284000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag066\/8497598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3,9]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag066","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,2,25]]},"article-number":"oyag066"}}